MBMichael R. Bristow

Michael R. Bristow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael R. Bristow has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiac resynchronization therapy and adrenergic mechanisms

    by Michael R. Bristow

    Cardiac resynchronization therapy (CRT) is a major advance in the treatment of heart failure (HF), and thus far the most important HF therapeutic modality identified in the 21st century. When applied to patients with left ventricular dyssynchrony, CRT immediately improves chamber contractile performance and myocardial efficiency. These salutary effects eventually result in reverse remodeling, improved functional capacity and symptoms, and a reduction in the major clinical outcomes of mortality and hospitalizations. The mechanisms that link the immediate effects of CRT and the chronic beneficial effects on myocardial and clinical end points have not been identified, however. One of the candidates for this linkage is a reduction in myocardial adrenergic stimulation, or normalization/attenuation of a mechanism known to promote progressive remodeling and HF. This possibility is raised by recent data in support of an “antiadrenergic hypothesis” of CRT ([13][1]). Unlike other HF treatments, CRT produces major improvements in all dimensions ([1][2]) of the heart failure syndrome, including mortality ([2][3], [3][4]), hospitalizations ([2][3], [3][4]), exercise tolerance ([2][3]–[4][5]), and quality of life ([2][3]–[4][5]). Beyond the absolute therapeutic benefit, CRT also demonstrates that devices, in addition to drugs, may have a profound impact on HF natural history. How does CRT work? In a general sense, it partially reverses chamber contractile dysfunction caused by regional delays in left ventricular conduction, typically to the lateral wall in the setting of a left bundle branch block. The result of resynchronizing ventricular conduction and subsequent cardiac myocyte depolarization is more efficient and simultaneous contraction of the entire left ventricle, compared with the dyssynchronous, to-and-fro wall motion characteristic of regional conduction delays. This resynchronization of contraction immediately improves systolic function and myocardial efficiency, reduces wall stress, and reduces mitral regurgitation ([5][6], [6][7]). Later, when measured at 3–6 mo ([7][8]), ventricular remodeling (pathological hypertrophy/chamber dilation) improves. The later favorable effects are likely due to the reduction in wall stress ([8][9]), but details of the therapeutic mechanisms are yet to be determined. From a HF clinical care standpoint, CRT is an example of the future of medical therapy: specific targeting of a subpopulation based on a surrogate marker (electrocardiographic QRS lengthening) that identifies a responsive subpopulation. That is, if this therapy were applied to the general HF population, where dyssynchrony amenable to correction by biventricular pacing may be present in only a minority of patients, CRT would likely not be efficacious, at least demonstrable within the sample sizes that are usually within reach of sponsors' budgets. There now is a very concerted effort to identify biomarkers, particularly pharmacogenetic, to accomplish the same thing with pharmacological therapy. This has already met with some success ([9][10], [10][11]) and is being incorporated into the drug development process ([11][12]). As it stands, the clinical response rate to CRT in a population of patients enriched in mechanical dyssynchrony by electrocardiographic criteria appears to be in the 60–70% range ([12][13], [13][1]), but this figure incorporates a relatively high placebo response rate ([12][13]). With CRT therapy, one of the remaining challenges is to thoroughly investigate and elucidate the precise mechanisms by which clinical and remodeling improvements occur. These are almost certainly linked phenomena, and so studies of remodeling should be considered clinically relevant. It would seem likely that the favorable antiremodeling effects of CRT are derivative of the initial favorable effects on chamber contractile performance ([8][9]). However, there are multiple possible cardiac myocytic signaling processes involved, as well as novel, yet to be identified mechanisms. A mechanism known to be extremely important in the natural history of HF is cardiac adrenergic mechanisms, and an effect of CRT on adrenergic activity has been suggested by some ([14][14]) but not all ([15][15]) previous studies. In this issue of the American Journal of Physiology-Heart and Circulatory Physiology , Najem et al. ([13][1]) provide evidence that a favorable effect on adrenergic drive may be an important determinant of CRT response. In this study, “responders” to CRT (as determined by New York Heart Association Class improvement) demonstrated an increase in microneurographically measured femoral sympathetic nerve activity (MSNA) when the biventricular pacing mode of CRT was turned off, leaving the patient with a left bundle branch block and presumed left ventricular dyssynchrony. No such increase in MSNA occurred in nonresponders when biventricular pacing was stopped. Although there are design weaknesses in the Najem et al. ([13][1]) study, such as the method of identification of responders and the lack of any baseline myocardial functional or adrenergic data, the results clearly suggest an antiadrenergic role of CRT in producing a favorable clinical response. The confirmation of this hypothesis and the explanation for a reduction in adrenergic drive in some patients but not others will need to be determined in future studies. Finally, there are several possible mechanisms by which CRT could reduce adrenergic drive, including a lowering of ventricular filling or central venous pressures ([16][16]) that are excitatory to adrenergic activity, and/or a resetting of impaired baroreflexes ([17][17]). These and other possible mechanisms also need to be investigated in additional studies. 1. [↵][18] Rivera D and Bristow MR. Cardiac resynchronization–a heart failure perspective. Ann Noninvasive Electrocardiol 10, Suppl 4: 16–23, 2005....


  • Cardiac Resynchronization—A Heart Failure Perspective

    by Dee Ann Rivera, Michael R. Bristow

    Over the past 15-20 years the development of new heart failure pharmacologic therapy has lowered mortality by 30-40% for this serious and prevalent clinical syndrome, within clinical trials conducted in patients with a dilated cardiomyopathy phenotype. However, over the past 5 years progress in the development of additional effective drugs has slowed, in part due to the success of neurohormonal inhibitors, on which background new therapies must be developed. That there is not an absolute ceiling on the development of new heart failure therapies has been convincingly recently demonstrated in electrophysiologic device trials, conducted on the background of maximal neurohormonal inhibition. Two trials, COMPANION and CARE-HF, have demonstrated unambiguously that in advanced heart failure patients with a marker of mechanical intraventricular dyssynchrony, increased QRS duration, cardiac resynchronization therapy in the form of biventricular pacing can improve major clinical outcomes including mortality. In addition, COMPANION also demonstrated that the addition of an ICD further improved mortality reduction, by lowering the incidence of sudden death. These trials indicate that device/drug therapy is at least additive in the treatment of heart failure, and they herald a new era in the multi-modality approach to therapeutics.


  • The COMET Trial

    by Michael R. Bristow, Kirkwood F. Adams, Jerry L. Bauman, Arthur M. Feldman, Thomas D. Giles, Sidney Goldstein, Douglas L. Mann, Robert L. Talbert


  • Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the β-Blocker Evaluation of Survival Trial

    by M.R. Bristow, H. Krause-Steinrauf, R. Nuzzo, Cheng-Seng Liang, J. Lindenfeld, B.D. Lowes, B. Hattler, W.T. Abraham, L. Olson, S. Krueger, et al.

    Background— Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results— Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant ( P Conclusions— In BEST, a subset of patients treated with bucindolol had an increased risk of death as the result of sympatholysis, which compromised the efficacy of this third-generation β-blocker.


  • Top Cited Papers
    Open Access

    Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure

    by Michael R. Bristow, Leslie A. Saxon, John Boehmer, Steven Krueger, David A. Kass, Teresa De Marco, Peter Carson, Lorenzo DiCarlo, David DeMets, Bill G. White, et al.

    We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays.


  • Altered Expression of Endothelin Receptors in Failing Human Left Ventricles

    by Koji Asano, Teresa J. Bohlmeyer, Jay Y. Westcott, Lawrence Zisman, Koichiro Kinugawa, Matthew Good, Wayne A. Minobe, Robert Roden, Eugene E. Wolfel, Joann Lindenfeld, et al.


  • Of Phospholamban, Mice, and Humans With Heart Failure

    by Michael R. Bristow

    Espite recent advances in the medical treatment of chronic heart failure, 1 this clinical syndrome remains progressive. For example, in recently completed clinical trials demonstrating a reduction in mortality by medical therapy with ␤-blockade 2,3 or spironolactone, 4 the survival curves of the active treatment groups retained a downward slope, such that at 20 to 24 months after randomization, only 80% to 85% of subjects with mild to moderate 2,3 and 70% of subjects with advanced 4 heart failure remained alive. The progressive nature of heart failure is due to the inexorable worsening of the underlying disease processes, myocardial dysfunction, and remodeling. 5,6 What are the critical factors responsible for progressive contractile dysfunction and remodeling of the failing heart? Data from clinical studies implicate both the adrenergic and reninangiotensin-aldosterone systems, because treatment with ␤-blocking agents and renin-angiotensin-aldosterone system inhibitors attenuate the dysfunction/remodeling processes. 6 Other signaling pathways are also involved, as shown by studies in animal models 7 and the failure of inhibiting both the adrenergic and renin-angiotensin-aldosterone systems to completely prevent progression in dysfunction, remodeling, and mortality. The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.